{"id":637112,"date":"2023-02-06T20:40:02","date_gmt":"2023-02-06T20:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637112"},"modified":"2023-02-06T20:40:02","modified_gmt":"2023-02-06T20:40:02","slug":"ankylosing-spondylitis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-ucb-biopharma-celgene-inmagene-biopharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ankylosing-spondylitis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-ucb-biopharma-celgene-inmagene-biopharmaceuticals_637112.html","title":{"rendered":"Ankylosing spondylitis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies &#8211; UCB Biopharma, Celgene, Inmagene Biopharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1675678659.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ankylosing spondylitis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - UCB Biopharma, Celgene, Inmagene Biopharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1675678659.jpeg\" alt=\"Ankylosing spondylitis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - UCB Biopharma, Celgene, Inmagene Biopharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Ankylosing spondylitis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong> &ldquo;Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ankylosing-spondylitis-as-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ankylosing spondylitis Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Ankylosing Spondylitis (AS) also called as Bechterew&#8217;s disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Ankylosing spondylitis usually starts with dull pain in the lower back and back stiffness. Some people with ankylosing spondylitis have &#8220;flares&#8221; of increased pain and stiffness that may last for several weeks before decreasing again.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Ankylosing spondylitis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Ankylosing spondylitis market size was valued at <strong>USD 4200 Million<\/strong> in the year 2021 and is anticipated to grow with a significant CAGR during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>In the <strong>United States<\/strong>, ankylosing spondylitis is almost undiagnosed in roughly <strong>50%<\/strong> of cases because of its mild course<\/li>\n<li>The total prevalent population of Ankylosing spondylitis in seven major markets is <strong>2,282,664<\/strong> in 2021. These cases are estimated to increase in the forecast period<\/li>\n<li>Among EU5 countries, Italy had the highest number of diagnosed prevalent cases for AS <strong>(191,566 cases)<\/strong>, while UK had the least cases <strong>(54,634)<\/strong> in 2021<\/li>\n<li><strong>Key Ankylosing spondylitis Companies:<\/strong> UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, and others<\/li>\n<li><strong>Key Ankylosing spondylitis Therapies:<\/strong> Bimekizumab, CC-99677, ABY-035, and others<\/li>\n<li>The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Ankylosing spondylitis Market Report &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-as-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-as-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Ankylosing spondylitis Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Ankylosing spondylitis market report covers a descriptive overview and comprehensive insight of the Ankylosing spondylitis Epidemiology and Ankylosing spondylitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Ankylosing spondylitis market report provides insights on the current and emerging therapies.<\/li>\n<li>Ankylosing spondylitis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Ankylosing spondylitis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Ankylosing spondylitis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-as-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ankylosing spondylitis Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. &nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Ankylosing spondylitis<\/li>\n<li>Prevalent Cases of Ankylosing spondylitis by severity<\/li>\n<li>Gender-specific Prevalence of Ankylosing spondylitis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Ankylosing spondylitis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Ankylosing spondylitis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-as-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ankylosing spondylitis market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Bimekizumab:<\/strong> UCB Biopharma<\/li>\n<li><strong>CC-99677:<\/strong> Celgene<\/li>\n<li><strong>ABY-035:<\/strong> Inmagene Biopharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Research and development strategies<\/li>\n<li>Awareness about the Disease<\/li>\n<li>Increasing prevalence<\/li>\n<li>The introduction of novel products<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Ankylosing spondylitis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Ankylosing spondylitis Companies:<\/strong> UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, and others<\/li>\n<li><strong>Key Ankylosing spondylitis Therapies:<\/strong> Bimekizumab, CC-99677, ABY-035, and others<\/li>\n<li><strong>Ankylosing spondylitis Therapeutic Assessment:<\/strong> Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies<\/li>\n<li><strong>Ankylosing spondylitis Market Dynamics:<\/strong>&nbsp;Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Ankylosing spondylitis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Ankylosing spondylitis Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ankylosing spondylitis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The introduction of novel products<\/li>\n<li>Increasing prevalence<\/li>\n<li>Awareness about the Disease<\/li>\n<li>Research and development strategies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Ankylosing spondylitis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Ankylosing spondylitis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Ankylosing spondylitis<\/p>\n<p style=\"text-align: justify;\">4. Ankylosing spondylitis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Ankylosing spondylitis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Ankylosing spondylitis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Ankylosing spondylitis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Ankylosing spondylitis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Ankylosing spondylitis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Ankylosing spondylitis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Ankylosing spondylitis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Ankylosing spondylitis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Ankylosing spondylitis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Ankylosing spondylitis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Ankylosing spondylitis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Ankylosing spondylitis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Ankylosing spondylitis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Ankylosing spondylitis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Ankylosing spondylitis treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-as-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ankylosing spondylitis Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ankylosing-spondylitis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-ucb-biopharma-celgene-inmagene-biopharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ankylosing-spondylitis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-ucb-biopharma-celgene-inmagene-biopharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Ankylosing spondylitis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics. DelveInsight&rsquo;s &ldquo;Ankylosing spondylitis Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ankylosing-spondylitis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-ucb-biopharma-celgene-inmagene-biopharmaceuticals_637112.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-637112","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=637112"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=637112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=637112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=637112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}